The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report

Sclerosing epithelioid fibrosarcoma is an ultra-rare and aggressive high-grade fibrosarcoma that was originally described in 1995. More than 100 cases are documented worldwide, with the most extensive case series reporting a high rate of recurrence and metastasis. ALK mutations are commonly seen in soft-tissue sarcomas; however, this is the first known case of an ALK V757M mutation. Here, we present a case using crizotinib in treating an ALK-positive sclerosing epithelioid fibrosarcoma refractory to all traditional treatment options.

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource
Language
Englisch

Bibliographic citation
The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report ; volume:16 ; number:1 ; year:2023 ; pages:746-752 ; extent:7
Case reports in oncology ; 16, Heft 1 (2023), 746-752 (gesamt 7)

Creator
Badran, Ahmed
Steele, Clara
Alquaydheb, Hisham
Ba Theeb, Ahmed
Bawazir, Abdulmalek
Elshenawy, Mahmoud A.
Atallah, Jean Paul

DOI
10.1159/000532099
URN
urn:nbn:de:101:1-2023122723533616643052
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:26 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Associated

  • Badran, Ahmed
  • Steele, Clara
  • Alquaydheb, Hisham
  • Ba Theeb, Ahmed
  • Bawazir, Abdulmalek
  • Elshenawy, Mahmoud A.
  • Atallah, Jean Paul

Other Objects (12)